GSK, Genmab fail to get NICE nod for leukemia drug

06/23/2010 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence decided not to endorse GlaxoSmithKline and Genmab's leukemia drug Arzerra, citing lack of evidence on the drug's effectiveness compared with standard treatment. GSK recently failed to gain NICE recommendation for cancer medicine Tyverb and platelet drug Revolade.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY